Induction therapy for cryptococcal meningitis in HIV infection: which regimen is preferred for induction?

• A. Fluconazole alone
• B. Amphotericin B deoxycholate alone
• C. Voriconazole plus flucytosine
• D. Amphotericin B (liposomal) plus flucytosine

Answer: (D)

The key idea is that rapid, fungus-killing therapy during induction is best achieved with a combination that has proven synergy and tolerability. Amphotericin B given in its liposomal form paired with flucytosine provides strong fungicidal activity against cryptococcus and accelerates clearance of the organism from the CSF, which translates into better survival for HIV-associated cryptococcal meningitis. The liposomal formulation reduces nephrotoxicity and other side effects, making it feasible to use for the needed induction period. Flucytosine is essential in this pairing because it enhances the overall activity of amphotericin B, leading to faster CSF sterilization than regimens that use amphotericin alone or other antifungals.

In contrast, fluconazole alone lacks the rapid fungicidal effect needed for induction and would not provide as effective clearance. Amphotericin B deoxycholate without flucytosine carries more toxicity and misses the synergistic benefit of the combination. Voriconazole with flucytosine isn’t the standard induction regimen given limited supporting data and guideline consensus. So the combination of liposomal amphotericin B plus flucytosine is the regimen most strongly supported for induction therapy.